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Meta-analysis a b s t r a c t  
The effect of supplementation with zinc on levels of IGF-1 remains relatively unexplored, and many of 
previous studies have reported equivocal findings. Thus, the aim of this study was to elucidate the influ-
ence of zinc on IGF-1. A complete systematic search was executed in Scopus, Web of Science, Embase, and 
PubMed/MEDLINE, by reviewers, from database inception until June 2019. Weighted mean difference 
(WMD) with the 95% CI was used for assessing the effects of zinc on IGF-1. We evaluated between study 
heterogeneity using the I-squared and the Q-test statistic. Ten studies reported changes in plasma levels 
of IGF-1. Combined results ascertained an increase in IGF-1 levels following zinc administration (WMD: 
8.620 ng/ml, 95% CI: 1.126, 16.113, I2 = 97.3%). Subgroup analyses demonstrated that zinc intake dosage 
10 mg/day (WMD: 9.50 ng/ml, 95% CI: 1.47, 17.53) and intervention length ˃8 weeks (WMD: 10.08 ng/ 
ml, 95% CI: 0.67, 19.48) significantly greater increased IGF-1 levels. The present study demonstrated that 
zinc supplementation can elicit significant increases in IGF-1 in humans. In addition, greater increments 
were observed when zinc intake dosage was 10 mg/day and intervention duration ˃8 weeks. 
 2020 The Authors. Published by Elsevier B.V. on behalf of King Saud University. This is an open access 
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Zinc is a ubiquitous, divalent, metal cation that is an essential 
component in 10% of human proteins and is a key micronutrient 
in cell signaling. Zinc is found in high concentrations in the b-
cells of the human pancreas, where it plays significant role in insu-
lin and glucagon secretion (Zhao et al., 2019). The effects of zinc on 
human health are, however, pleiotropic, where it is involved in the 
activation of certain enzymes, immune response, cell growth and 
proliferation, and, as a co-factor, in conferring protection against 
oxidative stress and inflammation (Prasad and Bao, 2019). Distur-
bances of zinc homeostasis have been shown to be involved in var-
ious non-communicable diseases, such as type 2 diabetes, growth 
retardation, age-mediated macular deterioration, alcohol-related 
liver disorder or sickle cell anemia (Fernandez-Cao et al., 2019; 
Prasad and Bao, 2019). Zinc is an important factor in growth and 
development in humans, mainly due to its crosstalk at a cellular 
level with insulin-like growth factor-binding protein 3 (IGFBP-3), 
growth hormone (GH), and insulin-like growth factor 1 (IGF-1). 
Thus, it is unsurprising that zinc deficiency can result in growth 
retardation and impaired bone metabolism (Adriani and 
Wirjatmadi, 2014; Alves et al., 2012). 
Insulin-like growth factor 1 (IGF-1) is a growth factor synthe-
sized in the liver, and elicits a myriad of effects on health due to 
its participation in the GH-IGF-1 axis, where it is involved in tissue 
homeostasis, has anti-apoptotic, mitogenic, anti-inflammatory, 
antioxidant and metabolic actions, contributes to skeletal muscle 
plasticity, maintenance of muscle strength and muscle mass, neu-
ral and cardiovascular protection, development of the skeleton, 
possesses insulin-like effects, and is a key factor in brain, eye and 
lung development during fetal development (Blanco-Alvarez 
et al., 2015; Hellstrom et al., 2016; Maggio et al., 2013; Vitale 
et al., 2019). As an anabolic hormone, IGF-1 plays important roles 
in both growth and development, and its levels vary depending 
on age, with peaks generally observed in the postnatal period 
and at puberty (Cho et al., 2019; Rahmani et al., 2019). Via a neg-
ative feedback loop, IGF-1 levels influence the release of GH from 
the hypophysis (Himoto and Masaki, 2018), where some of the 
actions of GH include, stimulation of glucose and amino acid, cell 
cycle regulation, are IGF-1 dependent (Alvarez-Nava and Lanes, 
2017; MacDonald, 2000). 
IGF-1 levels are not constant throughout the life course but 
decrease with age as a reflection of the actions of GH. Following 
puberty, during the third decade of life, a rapid decrease in IGF-1 
levels is registered. Whilst between the third and the eighth dec-
ade of life, IGF-1 levels decrease gradually, but appear unrelated 
to functional decline (Janssen, 2018; Newman et al., 2016; 
Wennberg et al., 2018). The impact of zinc on plasma levels of IGF-1 remains relatively 
unexplored and many of the previous studies have shown conflict-
ing results (Berger et al., 2015; Blostein-Fujii et al., 1997; Clark 
et al., 1999; Ninh et al., 1996; Rodondi et al., 2009). Thus, the 
aim of this study was to elucidate the influence of zinc intervention 
on IGF-1 levels in humans. 2. Methods 
2.1. Study design and search strategy 
This present study was conducted in accordance with the Pre-
ferred Reporting Items for Systematic Review and Meta-analysis 
(PRISMA) guidelines (Moher et al., 2015). An electronic search 
was performed in Web of Science, Scopus, PubMed/MEDLINE, 
and EMBASE by the authors, from database inception until June 
2019. We provided search strategy keywords in Supplementary 
Table 1. 2.2. Selection criteria 
We followed the participant, intervention, comparison, out-
come, time, and study design (PICOTS) items to define publication 
inclusion/exclusion criteria. 
Two independent investigators screened the title and abstract 
of all articles to ascertain eligible studies and in the next step, 
reviewed the full-manuscripts of the selected studies inclusion cri-
teria were: 1. Controlled Trial studies in human adults (either par-
allel or crossover designs); 2. Studies measured circulating IGF-1 at 
baseline and end of treatment, or reported IGF-1 change for inter-
vention/control groups 2. Compared oral zinc administration with 
the control group. Moreover, studies not providing concentrations 
of IGF-1 pre and post treatment, animal studies, studies without a 
comparative group, review articles, abstracts from conferences, 
and commentaries were excluded. 2.3. Data extraction 
Two reviewers performed the data extraction and a chief 
researcher resolved any disputes with discussion. Study authors, 
country, year of publication, sample size of studies, participants’ 
gender, duration of intervention, mean age, study design 
(parallel/cross-over), zinc dosage, and averages and associated 
standard deviations (SD) of IGF-1 circulation at beginning, end 
intervention or/and alterations between beginning and end 
intervention. 
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Table 1 
Characteristics of included studies. 
Author Country (year) Participants Duration Gender Sample Size Dose 
(week) case/placebo 
Berger et al. USA (2015) Premenarcheal Girls 4 female 75/75 9 mg.day 
Adriani et al. Indonesia (2014) stunted children 24 both 12/12 0.37 mg.day 
Rodondi et al. Switzerland FRAIL ELDERLY 4 both 25/22 30 mg.day 
(2009) 
Az-Gomez et al. Spain (2003) Preterm Infants 24 both 18/16 10 mg.day 
Porto1 et al. Brazil (2000) Children with Short Stature 24 both 18/18 5 mg.kg.day 
Nishiyama et al. Japan (1999) Pregnant Women 8 female 17/10 34 mg.day 
Hershkovitz et al. Israel (1999) Infants with Nonorganic Failure to Thrive 12 both 14/11 2 mg.kg.day 
Blostein et al. USA (1997) women with noninsulin-dependent diabetes 3 female 20/20 30 mg.day 
mellitus 
Clark et al. UK (1999) pubertal girls 6 female 24/19 15 mg.day 
Ninh et al. Vietnam (1996) children 20 both 24/18 10 mg.day 
Table 2 
Quality assessment of study included in this study. 2.4. Quality assessment 
The quality assessment of RCT’s were surveyed by means the 
Cochrane Collaboration’s tool (Higgins et al., 2011), which com-
posed of the following tenets: 1) allocation concealment, 2) ran-
dom sequence generation, 3) incomplete outcome data, 4) 
blinding of participants, 5) personnel, blinding of outcome assess-
ment, 6) selective reporting, 7) and other possible sources of 
biases. 2.5. Statistical analysis 
Weighted mean differences (WMD) in addition to 95% CI were 
used to assess effect of zinc supplementation on IGF-1 levels. If 
the mean change SD was not identifiable in the included trials, 
we utilized the next formula to calculate it: SDalteration = square root 
[(SD baseline*SDbaseline + SDfinal*SDfinal)  (2  R  SDbaseline  SDfinal)] 
(Borenstein et al., 2009). Pooled WMD from qualified trials was cal-
culated using the derSimonian and Laird random-effects approach. 
We evaluated the heterogeneity between studies using the Q-test 
and the I-squared statistic with significant levels set at a p-value 
<0.10. Subgroup analyses were used to identify the sources of 
heterogeneity among the included studies. Publication bias was 
discovered through funnel plot examination, in addition to Egger’s 
method and Begg’s method, respectively. The possible impact of 
zinc dosage and treatment duration was assessed by means frac-
tional polynomial approaches within non-linear dose-response 
analyses, in addition to conducting a meta-regression. All statisti-
cal analyses were implemented utilizing Stata program (Stata Corp. 
College Station, Texas, USA) and an a priori p-value  0.05 was used 
to demarcate statistical significance. 3. Results 
The initial search yielded 606 studies from PubMed/Med-line, 
Scopus, Web of Science, and Embase. After duplicates were 
removed, 317 studies remained for further assessment. Following 
screening against inclusion criteria, 286 publications were 
excluded and 31 trials were eligible for full-text extraction. Subse-
quently, 21 studies were ruled out for the following reasons: 1) no 
data of interest were evident 2) and non-randomized controlled 
trial (RCT) design, Lastly, ten publications were inserted in the 
quantitative meta-analysis (Adriani and Wirjatmadi, 2014; Berger 
et al., 2015; Blostein-Fujii et al., 1997; Clark et al., 1999; Diaz-
Gomez et al., 2003; Hershkovitz et al., 1999; Ninh et al., 1996; 
Nishiyama et al., 1999; Porto et al., 2000; Rodondi et al., 2009). 
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Fig. 1. Forest plot of randomized controlled trials investigating the effects of zinc supplementation on IGF-1 levels. 
Table 3 
Pooled estimates of effects on IGF-1 within different subgroups. 
Group No of comparisons WMD (95% CI) P value P-heterogeneity I2 (%) 
Zinc supplementation dosage (mg/day) 
10 6 9.50 (1.47–17.53) 0.020 0.000 98.5 
˃10 4 2.45 (18.56 to 23.47) 0.819 0.304 17.5 
Intervention duration (week) 
8 5 6.27 (12.67 to 25.21) 0.517 0.000 83.6 
˃8 5 10.08 (0.67–19.48) 0.036 0.000 98.7 
Type of population 
Preterm Infants 2 19.20 (17.37–21.03) 0.000 0.366 0.0 
Children 5 9.26 (2.24–16.27) 0.010 0.000 94.9 
adult 3 5.48 (17.43 to 6.46) 0.368 0.298 17.4 3.1. Study characteristics 
Features of all included trials are summarized in Table 1. There 
were 247 and 218 sample size in zinc and control groups, 
respectively. Dose of zinc intervention ranged between 0.37 and 
34 mg/day. Two arms were employed in the USA (Berger et al., 
2015; Blostein-Fujii et al., 1997), one in Indonesia (Adriani and 
Wirjatmadi, 2014), one in the UK (Clark et al., 1999), one in Viet-
nam (Ninh et al., 1996), one in Switzerland (Rodondi et al., 
2009), one in Spain (Diaz-Gomez et al., 2003), one in Brazil 
(Porto et al., 2000), one in Japan (Nishiyama et al., 1999) and one 
in Israel (Hershkovitz et al., 1999). Included studies were published 
between 1996 and 2015. The mean follow up of treatment was 
12 weeks. All publication were clinical trials. Most publications 
were implemented on both genders (Adriani and Wirjatmadi, 
2014; Diaz-Gomez et al., 2003; Hershkovitz et al., 1999; Ninh 
et al., 1996; Porto et al., 2000; Rodondi et al., 2009) and four con-
ducted on women (Berger et al., 2015; Blostein-Fujii et al., 1997; 
Clark et al., 1999; Nishiyama et al., 1999). Table 2 detailed the sum-
mary results of the quality assessment of meta analyses. Three 
studies were of fair quality (Blostein-Fujii et al., 1997; Clark 
et al., 1999; Rodondi et al., 2009), 6 were of good quality 
(Adriani and Wirjatmadi, 2014; Berger et al., 2015; Diaz-Gomez et al., 2003; Hershkovitz et al., 1999; Ninh et al., 1996; Porto 
et al., 2000), and one was of poor quality (Nishiyama et al., 1999). 
3.2. Meta-analysis results 
Ten studies providing a total of 465 (case = 247, control = 218) 
individuals published alterations in IGF-1 plasma levels as an out-
come measure. The random-effects model asserted an significant 
elevate in IGF-1 after zinc administration (WMD: 8.620 ng/ml, 
95% CI: 1.126–16.113, p = 0.024; Fig. 1). Nevertheless, a significant 
high of heterogeneity was discovered in the meta-analysis 
(p = 0.000, I2 = 97.3%). 
3.3. Subgroup analysis 
We stratified trials across zinc intake dosage and intervention 
duration (week) (Table 3). The analyses demonstrated that zinc 
intake dosage 10 mg/day (WMD: 9.50 ng/ml, 95% CI: 1.47– 
17.53, I2 = 98.5%) increased IGF-1 significantly more than zinc 
intake dosage >10 mg/day (WMD: 2.45 ng/ml, 95% CI: 18.56– 
23.47, I2 = 17.5%). Furthermore, follow up duration >8 weeks 
(WMD: 10.08 ng/ml, 95% CI: 0.67–19.48, I2 = 98%) improved IGF-
1 significantly more than 8 weeks (WMD: 6.27 ng/ml, 95% CI: 
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Fig. 2. A) Dose-response analysis – zinc intake dosage (mg/day) and intervention duration (week) with IGF changes. Weighted mean difference, WMD, B) Meta regression 
analysis (Zinc intake dosage (mg/day) and intervention duration (week) with IGF changes). 
Fig. 3. Funnel plot of the weighted mean difference (WMD) versus the s.e. of the 
weighted mean difference (WMD). 12.67–25.21, I2 = 83%). Additionally, among preterm infants, zinc 
administration resulted in a greater increase in IGF-1 (WMD: 
19.20 ng/ml, 95% CI: 4.99–6.54, I2 = 0.0%) than children (WMD: 
9.26 ng/ml, 95% CI: 2.24–16.27, I2 = 94%); however, it did not influ-
ence IGF-1 levels in adult subjects (WMD: 5.48 ng/ml, 95% CI: 
17.43–6.46, I2 = 17%). 3.4. Dose-response analysis and meta regression 
Dose-response analysis and meta regression of the follow-up 
duration and zinc intake dosage with alterations in plasma IGF-1 
did not reveal a significant association (Fig. 2). 
3.5. Sensitivity analysis and publication bias 
The Begg’s and Egger’s tests, did not highlight any publication 
bias in the meta-analysis (p = 0.721 and p = 0.531, respectively). 
Visual inspection of funnel plot also demonstrated no evidence of 
the presence of publication bias (Fig. 3). To explore the influence 
of any individual study on the pooled effect, we iteratively omitted 
each study and assessed the impact. Accordingly, we found no sig-
nificant effects of any one trial on the overall effect. 
4. Discussion 
Our meta-analysis of 10 clinical trials, which included 465 sub-
jects, revealed that zinc supplementation yields a significant rise in 
IGF-1 levels in humans. Our findings from subgroup analyses sug-
gested that the effect of zinc supplementation on levels of IGF-1 in 
humans depends, not only on the dosage, but also on the duration 
of the intervention and on the age of the participants. 
Our results show that daily zinc intake 10 mg increased IGF-1 
significantly more versus a daily intake of zinc >10 mg/day. Thus, 
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increasing IGF-1 levels and that an excessive daily intake of zinc 
does not yield any considerable benefits. However, some studies 
have argued that zinc supplementation has no effect on IGF-1 
levels. Our results contradict the findings of a prior study by Barf-
four et al. who concluded that the administration of zinc (in 7 mg 
tablets or micronutrient powder consisting of 10 mg zinc + 6 mg 
iron +13 other micronutrients) in 419 Laotian children did not 
increase IGF-1 levels (Barffour et al., 2019). Normal daily intake 
of zinc in humans is estimated at 14–30 mg/day, but values 
between 2.8 and 40 mg/day can, reportedly, yield physiological 
zinc homeostasis, whilst excess zinc is eliminated mainly via the 
gastrointestinal tract (Roohani et al., 2013). 
Further, we showed that zinc supplementation >8 weeks 
increased IGF-1 significantly more versus zinc supplementation 
8 weeks. Our findings might be related to the prior serum zinc 
concentrations of the subjects who were given zinc supplements, 
and that a supplementation of >8 weeks is required to replenish 
zinc deposits in zinc deficient patients. Zinc supplementation 
increases IGF-1 levels in both zinc-deficient and normal, non-
zinc-deficient, subjects (Rocha et al., 2015). However, previous 
reports have asserted that zinc supplementation is more effective 
in patients who have a zinc deficiency and non-normal serum zinc 
levels. Park et al. studied the effect of zinc supplementation on IGF-
1 levels in children diagnosed with failure-to-thrive; however, 
study cessation, they found no significant modifications in serum 
IGF-1 levels in these participants, attributing this result to the fact 
that the study group had normal zinc and IGF-1 values prior to the 
zinc intervention (Park et al., 2017). 
The most prominent finding of the present study was that the 
influence of zinc supplementation on IGF-1 levels depends on the 
age category in which the intervention was delivered. Among pre-
term infants, zinc administration resulted in a greater increase in 
IGF-1 levels versus children, whereas it did not influence IGF-1 
levels in adults. Firstly, these results confirm the hypothesis of 
Akram et al., that zinc is an essential factor in preventing prema-
ture birth (Akram et al., 2011). Zinc is an essential trace element 
for human health, earning its colloquial title of ‘the metal of life’, 
due to its participation in cell growth, immunity, tissue repair, syn-
thesis of proteins and of the DNA, thyroid gland and optimal bone 
functioning (Kaur et al., 2014; Maggio et al., 2013). Along with pro-
teins, phosphorus, magnesium, sodium and potassium, zinc is a 
type 2 nutrient whose deficiency results in the inhibition of linear 
growth (Millward, 2017). Zinc is required as early as fetal-placental 
development, where subjects who are small for their gestational 
age have lower body mass index, hemoglobin, iron, zinc and pla-
cental protein levels of IGF-1 as compared to infants measured as 
large for gestational age group (Akram et al., 2011). Thus, the 
authors suggested that zinc supplementation in pregnancy might 
decrease preterm birth risk, and elicit a positive impact on the out-
come of the pregnancy and on the infant’s birthweight (Akram 
et al., 2011). Interestingly, in murine models with zinc deficiency, 
IGF-1 levels can be corrected by stimulating caloric intake or by 
external administration, but these measures do not correct the 
growth retardation (MacDonald, 2000). 
Our results reinforce the concept that zinc supplementation 
provides benefits in children with growth disturbances related to 
zinc deficiency. Hamza et al. demonstrated that zinc supplementa-
tion leads to an increase in IGF-1 levels in Egyptian children who 
had a serum zinc deficit and short stature. In Hamza et al, the 
authors administered zinc supplements for a period of 3 months 
in 50 zinc-deficient pre-pubertal children and observed an elevate 
in serum zinc in 100%, IGF-1 concentrations in 40% and IGFBP-3 
levels in 40% of the study group, respectively, as well as an eleva-
tion of the height standard deviation score. However, despite the 
zinc supplementation, normal ranges of serum zinc, IGF-1 and IGFBP-3 were only noted in 64%, 40% and 22% of the children, 
respectively. Thus, an intervention >3 months might have been 
required in these children to normalize the concentrations of 
serum zinc, IGF-1 and IGFBP-3 (Hamza et al., 2012). Imamoglu 
et al. also confirmed the stimulatory effect of zinc treatment on 
IGF-1 levels, where 22 pre-pubertal children who received zinc 
supplements for 6 weeks registered an elevate in IGF-1 and 
IGFBP-3 concentrations as compared to baseline. On the other 
hand, children who had normal zinc levels and continued zinc sup-
plementation for 6–12 months did not register higher standard 
deviation scores for weight or height, implying that zinc supple-
mentation provides greater benefits mainly in zinc-deficient sub-
jects (Imamoglu et al., 2005). 
We also demonstrated that zinc supplementation at an older 
age did not increase IGF-1 levels. Maintaining high or low levels 
of IGF-1 in adults and the elderly remains a controversial topic, 
lacking consensus. Zinc is a micronutrient of paramount impor-
tance to the bioactivity of IGF-1, nevertheless, it should be taken 
into account that an increased bioactivity of IGF-1 has been linked 
to several types of malignancies, such as breast, prostate or col-
orectal cancer (Rahmani et al., 2019). On the other hand, there is 
evidence suggesting that higher IGF-1 are cardio- and neuro-
protective and thus beneficial (Janssen, 2018). Contrastingly, a 
meta-analysis by Burgers et al. suggested that, in adults, both 
decreased IGF-1 and increased IGF-levels are linked to increased 
all-cause mortality. Their research included 12 studies enrolling 
14,906 subjects and demonstrated, using a dose–response meta-
regression, that there is a U-shaped relationship between all-
cause mortality and IGF-1 levels (P = 0.003), as well as cardiovas-
cular and cancer-related mortality (Burgers et al., 2011; 
Gunawardane et al., 2015). In adults, the effects of zinc on IGF-1 
seem to have a different outcome versus children. These observa-
tions might be attributed to the installment of the somatopause 
during which GH and IGF-1 levels gradually decrease (Maggio 
et al., 2013). Thus, further studies are necessary to elucidate the 
roles of IGF-1 in health and disease, as well as the crosstalk 
between zinc supplementation and IGF-1 in humans. 
Our study has several limitations, however; for instance, there 
was large heterogeneity in study design, where a wide array of zinc 
dosages, and study durations were employed. Moreover, the stud-
ies included a range of subjects and ages, including women with 
noninsulin-dependent diabetes mellitus, frail elderly, children 
and preterm infants, all of whom may conceivably demonstrate 
differing concentrations of IGF-1, although this issue is, at least 
in part, moderated by considering modifications from baseline. 
Moreover, despite these heterogeneities, the random-effects model 
methodology used in the present study represents a significant 
benefit in being able to control for such factors. In addition, accord-
ing to the results of current study, more studies are needed in rela-
tion to zinc intake in the elderly, because zinc supplementation 
may be associated with prolonged life and aging process. 5. Conclusion 
The present study highlighted that zinc supplementation leads 
to a significant increase in IGF-1 in humans. In addition, greater 
increments were observed when zinc intake dosage was 
10 mg/day and intervention duration ˃8 weeks. Declaration of Competing Interest 
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